JPRN-UMIN000016078已完成未知
Evaluation of the safety and efficacy of low dose transgenic rice containing peptides from Japanese cedar pollen allergens. - Evaluation of the safety and efficacy of low dose transgenic rice containing peptides from Japanese cedar pollen allergens.
The Jikei University, School of Medicine0 个研究点目标入组 21 人开始时间: 2014年12月29日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) A person who is allergic to Rice or has a history of Rice allergy. 2) A person who shows Pet/House dust specific IgE antibody valued over Class V, and has pet (dogs and cats). 3) A person who is imperative to use medicine such as anti-allergic agent and steroidal chemicals that potentially influence the outcome of evaluation. 4) A person who underwent an operation that is accompanied to nasal disorder within last 2years, or has nasal disorder such as acute/chronic-rhinitis, rhinopolypus, hypertronic rhinitis, septal deviation, sinusitis which all are potentially hinder to the outcome of evaluation. 5) A person who has any disorders under treatment and the condition is unstable that trial investigator has asessed as mismatched participant. 6) A person who has a history of serious disorder such as diabetes, hepatic disorder, kidney disorder, and cardiac disorder. 7) A person who takes beta-blocker in order to treat complecating disorders such as hypertension, and / or cardiac disorder. 8) A person who takes alpha-blocker in order to treat complecating disorders such as prostatic hyperplasia. 9) A person who is complecated by immunodeficiency disorder, cancer, or severe enemia. 10) A person who is complecated by asthma. 11) A person who'S pre-clinical test showed AST(GOT), ALT(GRT), Creatinine or BUN value exceed 1.5 times the upper limit or normal, or has other laboratory abonormalities that trial investigator has assessed as mismatched participant. 12) A person who participates in other clinical test at the onset of this test. 13) A person who is presently breastfeeding, pregnant, or planning/wishing to be a pregnant during a period of this clinical test. 14) A person whom trial investigator has asessed as mismatched participant.
研究者
相似试验
招募中
4 期
A clinical trial to study the efficacy and safety of low dose versus standard dose emicizumab prophylaxis in haemophilia A patients.CTRI/2024/01/061593Department of Health Research, India
尚未招募
不适用
Assessment of effectiveness and safety of minimal doses of propofol for sedation for MRI in childreCTRI/2019/11/022044OKMANYA TILAK MUNICIPAL MEDICAL COLLEGE AND LOKMANYA MUNICIPAL GENERAL HOSPITA
进行中（未招募）
不适用
ow doses of Rituximab in Graves orbitopathyActive moderate to severe Graves OrbitopathyMedDRA version: 14.1Level: PTClassification code 10060742Term: Endocrine ophthalmopathySystem Organ Class: 10015919 - Eye disordersEUCTR2012-001980-53-ITFONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO10
招募中
不适用
Pilot study on the efficacy and safty of low-dose tocilizumab therapy in elderly RA patientsRheumatoid arthritisJPRN-UMIN000008185Kyushu University Beppu Hospital Department of Metabolism, Hematology and Rheumatic Diseases (DMHRDs)10
招募中
不适用
Evaluation of the effect of low-dose lung radiotherapy in the treatment of Covid 19Covid-19 Pneumonia.Pneumonia due to SARS-associated coronavirusJ12.81IRCT20201203049585N2Esfahan University of Medical Sciences36